Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Brand-name prescription medicine

Gobarden

Generic name: Bendamustine hydrochloride

FDA application holder: Avyxa Holdings

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Gobarden?
Gobarden is a brand name of Bendamustine hydrochloride, a prescription medicine. The FDA NDC Directory lists 1 Gobarden product in 1 strength and form.
Who makes Gobarden?
Avyxa Holdings holds the FDA application for Gobarden (NDA219014, approved July 3, 2025).
Is there a generic or store brand of Gobarden?
Other products of Bendamustine hydrochloride are listed with the FDA, but none in exactly the same strength and form as a Gobarden product.
Has Gobarden been recalled?
No recall linked to Gobarden products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Gobarden is

Each Gobarden product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Bendamustine hydrochloride · prescription medicine

Strength and formProduct namesSame medicine, other namesLabel
bendamustine hydrochloride 100 mg/4 mL
injection, solution (intravenous)
Gobarden None listed —

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Bendamustine hydrochloride →

FDA approval

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
FDA applications of Gobarden products (Drugs@FDA)
ApplicationHolderFirst approvedProducts
NDA219014Avyxa HoldingsJuly 3, 20251

Companies that list Gobarden

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Gobarden products.

Recalls

No recall linked to Gobarden products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers